Profusa (NASDAQ:PFSA) Raised to Sell at Wall Street Zen

Profusa (NASDAQ:PFSA) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Profusa in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Profusa Stock Performance

Shares of NASDAQ PFSA opened at $0.69 on Friday. The stock has a market cap of $941,120.00, a PE ratio of 0.00 and a beta of 0.28. Profusa has a 1-year low of $0.41 and a 1-year high of $180.00. The firm’s 50-day moving average price is $1.15.

Profusa (NASDAQ:PFSA) last released its earnings results on Wednesday, April 15th. The company reported $89.25 earnings per share for the quarter.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.